

YOU ARE INVITED TO JOIN US

Residual Risk Beyond LDL-C: A Practical Approach

This meeting will focus on the unmet clinical needs of high-risk, statin-treated cardiovascular patients and explore the concept of residual cardiovascular risk.

Join us for an insightful discussion on triglyceride-associated residual risk, the evidence supporting VAZKEPA®, and the evolving landscape of cardiovascular risk management across the Hunter New England Health District.



 DATE

THURSDAY
20 **AUG**
2026


 TIME

6:30PM

 VENUE

**NOAH's on the Beach,
29 Zaara St,
Newcastle East**

 PRESENTERS



Prof. Aaron Sverdlov

Heart Failure, Cardio-Oncology & General Cardiologist

Aaron Sverdlov is Professor and Director of Heart Failure at the University of Newcastle, Australia. Aaron is a clinician-scientist with track record in basic through to clinical research and has received more than \$18 million in research funding and co-authored >100 papers.



Dr Robert Hungerford

GP Supervisor and Hon Conjoint Lecturer at the University of Newcastle

Dr Robert Hungerford is a Fellow of the RACGP, recipient of the Tony Buhagiar Medal (2014) and has completed the Certificate of Excellence in Lipidology from the European Atherosclerosis Society. He is GP supervisor in a large teaching general practice in Newcastle, also working at a rapid access GP clinic at the John hunter hospital. He is conjoint lecturer at the university of Newcastle, is on the clinical council of the Australian Atherosclerosis Society and is regularly involved with education at a regional and national level in his areas of interest, namely ASCVD, Heart Failure and Diabetes.

REGISTER HERE:

www.seqiruseducationevents.com.au

ACCESS CODE:

VAZ26N



YOU ARE INVITED TO JOIN US

Residual Risk Beyond LDL-C: A Practical Approach

DATE: Thursday, 20 August 2026

VENUE: NOAH'S on the beach, 29 Zaara St, Newcastle East
Dinner will be served during presentation

AGENDA:

- 6:30 PM Arrival & Registration
- 7:00 PM Defining Residual Cardiovascular Risk: Beyond LDL-C
- 7:30 PM Translating REDUCE-IT¹ into Practice: Guidelines, PBS & Real-World Use
- 7:50 PM Local Implementation in Action: The Newcastle Experience
- 8:00 PM Panel Discussion & Audience Q&A
- 8:30 PM Meeting Close



REGISTER HERE:
www.seqiruseducationevents.com.au

ACCESS CODE:
VAZ26N

For further information, please contact your CSL Seqirus Representative.

Charlene Love

0438 351 716

charlene.love@seqirus.com

PBS Information: VAZKEPA[®] Authority Required (STREAMLINED). Refer to PBS schedule for full authority information.



Before prescribing, please review full Product Information available at www.cslseqirus.com.au/ products or by scanning the QR code

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems

Vazkepa Important safety information: Use with caution in patients with known hypersensitivity to fish and/or shellfish. Increased risk of atrial fibrillation or flutter with use, particularly in patients with a previous history of atrial fibrillation or flutter; monitor for clinical evidence of atrial fibrillation or flutter and perform electrocardiographic evaluation when clinically indicated. Increased incidence of bleeding; use with antithrombotic agents including acetylsalicylic acid, and/or anticoagulants may increase risk of bleeding; monitor periodically. The rates of serious adverse bleeding events was 2.7% in the VAZKEPA[®] group and 2.1% in the placebo group (p=0.06).^{1,2}

By registering for this event, you agree that you are a healthcare professional registered to practice in Australia and consent to your data being collected in accordance with the Seqirus Privacy Policy (www.csl.com/privacy-policy) and agree to receiving communications from Seqirus in relation to this event. As Seqirus abides by the Medicines Australia Code of Conduct, only invitees may attend this event. Any costs (e.g. travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional attending this event cannot be paid for or subsidised by Seqirus. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association.

Privacy Notice: Your personal information will be used by CSL and its group legal entities. ('we', 'us', 'CSL') in connection with registering your attendance at this event and sending you related communications. CSL may also use your personal information to email you about products or services, as elected by you. If your personal information is not provided it may not be possible to register you for the event. We may disclose personal information to third parties including Thrivase strictly for the purpose of hosting the event, in which case we will take appropriate measures to ensure your information is maintained securely and in confidence. Some of these entities (including CSL group entities) may be located overseas. The countries in which recipients may be located include (but are not limited to) the United States, Switzerland and countries within the European Union. Further information about how CSL may use your personal information, including how you can make an enquiry or exercise any rights in relation to your personal information is set out in our Privacy Policy available at <http://www.csl.com/privacy-policy>.

Abbreviations: LDL-C, low-density lipoprotein cholesterol; PBS, Pharmaceutical Benefits Scheme. **References:** 1. Bhatt DL et al. N Engl J Med 2019;380:11–22 (including suppl. appendix). 2. VAZKEPA[®] Product Information.

Seqirus (Australia) Pty Ltd. ABN 66 120 398 067, Melbourne, Victoria, 3008. www.seqirus.com.au.

Medical Information: 1800 642 865. VAZKEPA[®] is a registered trademark of Amarin Corp plc.

Seqirus[™] is a trademark of Seqirus UK Limited or its affiliates.

Date of preparation: July 2026. AU-VZKP-25-0088.

Vazkepa[®]
(icosapent ethyl)

This event is proudly presented by

CSL Seqirus